Stock Report: VIVUS Inc. (VVUS) Report Updated: May 20, 2013 | Print This Page
Report Features:
Stock Analysis
Rating: Monthly View
| A |  |
|
|
|
|
|
 |
|
|
 |
 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | ||||||||||||
| C | ||||||||||||
| D | ||||||||||||
| F | ||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Rating: Weekly View
| This Week: | F  no change |
|---|---|
| Last Week: | F no change |
| Two Weeks Ago: | F no change |
Company Profile
VIVUS, Inc., a biopharmaceutical company, is developing therapies to address obesity, sleep apnea, diabetes, and male sexual health. Its lead investigational product, Qnexa, has completed Phase 3 clinical trials for the treatment of obesity. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. The company’s investigational drug candidate also comprises avanafil, a Phase 3 clinical studies completed product to treat erectile dysfunction. VIVUS, Inc. has a licensing agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Avanafil. The company was founded in 1991 and is headquartered in Mountain View, California.
Recent News: VIVUS Inc.
| 2012-10-19 00:00:00 | Report of unscheduled material events or corporate changes - Form 8-K |
| 2012-10-18 17:30:03 | VIVUS Receives Formal Decision From CHMP |
| 2012-10-17 07:00:00 | VIVUS Submits REMS Amendment To FDA For Qsymia (Phentermine And Topiramate Extended-Release) Capsules CIV |
| 2012-10-17 00:00:00 | Report of unscheduled material events or corporate changes - Form 8-K |
| 2012-10-08 09:42:47 | Express Scripts Joins Qsymia(TM) (Phentermine and Topiramate Extended-Release) Certified Home Delivery Pharmacy Network |
My Portfolios (View All)
Save your portfolio—or a few for that matter—and check up on your stocks 24/7! Log in here.
Louis Navellier's Portfolios
- Blue Chip GrowthTop blue chips
- Emerging GrowthTop small-caps
- Ultimate GrowthFastest-moving
- Platinum GrowthElite Model Portfolio